ARCHIVES

Duke Halts Third Trial; Coauthor Disputes Claim That Data Validation Was Blinded

This article is from The Cancer Letter archive.

Vol. 35 No. 39 | October 23, 2009

Download PDF Visit The Full Archive

Related Articles

ODAC Okays First “Paper NDA,” By BMS For Bieomycin

October 1, 1993

Rosenberg’s Latest Results: 22% Response Seen With LAK/IL-2, 13% With High Dose IL-2 Alone

April 10, 1987

Two cancer center directors named: Michael Kastan at St. Jude, James Willson at Harold Simmons.

December 10, 2004

Rare Lung Disease Raises Risk Of Meningiomas

October 26, 2001

Digital Immunoassay PSA Test May Predict Cancer Recurrence

October 28, 2011

Saffiotti Couldn’t Cope With Demands Of National Program, Rauscher Says In Letter To Kennedy

June 11, 1976